<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00369226</url>
  </required_header>
  <id_info>
    <org_study_id>06-065</org_study_id>
    <secondary_id>X05175</secondary_id>
    <nct_id>NCT00369226</nct_id>
  </id_info>
  <brief_title>Bortezomib Plus Tacrolimus and Methotrexate to Prevent Graft Versus Host Disease (GVHD) After Mismatched Allogeneic Non-Myeloablative Blood Stem Cell Transplantation</brief_title>
  <official_title>Phase I/II Trial of Bortezomib (Velcade) in Addition to Tacrolimus and Methotrexate to Prevent Graft Versus Host Disease (GVHD) After Mismatched Allogeneic Non-Myeloablative Peripheral Blood Stem Cell Transplantation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Dana-Farber Cancer Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Brigham and Women's Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Millennium Pharmaceuticals, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Dana-Farber Cancer Institute</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine if Velcade (also known as bortezomib) can help
      prevent graft versus host disease (GVHD) developing after transplantation. This is done by
      using a combination of three immune suppressive medications: Velcade, tacrolimus and
      methotrexate. Stem cell transplantation is one of the options for patients with cancer of the
      blood or blood forming organs. Recently, allogeneic stem cell transplants have been performed
      using lower doses of chemotherapy and radiotherapy: non-myeloablative or &quot;mini&quot; transplants.
      GVHD is a significant problem that may occur even after &quot;mini&quot; transplantations. Information
      from other research studies, suggests that Velcade may help to reduce the risk of developing
      GVHD when given early after transplantation.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      -  In this study we are looking for the highest dose of Velcade that can be given to people
           safely when given with tacrolimus and methotrexate. Not everyone who participates in the
           study will receive the same amount of the study drug. The dose the participant will
           receive depends upon the number of subjects enrolled on the study and how well they have
           tolerated their doses of the drug.

        -  Before Transplant: In addition to the chemotherapy drugs, fludarabine and busulfex, for
           the participants non-myeloablative transplant, they will also start taking tacrolimus
           orally three days before their transplant.

        -  After Transplant Medication: Methotrexate; Intravenously on days 1, 3, 6 &amp; 11 after
           transplant for a total of 4 doses. Tacrolimus; Continue taking orally once daily.
           Velcade: Intravenously on days 1, 4 &amp; 7 after transplant, a total of 3 doses.
           Filgrastim: Subcutaneous injection daily starting the day after transplant and
           continuing until the participant blood counts have recovered.

        -  After Transplant Physical Exams &amp; Tests: Participants will have physical exams and blood
           tests every week for 1 month. After 1 month, a none marrow biopsy will be performed to
           look for evidence of the donor's cells in the participants bone marrow.

        -  Following the 1 month period of time, participants will be seen every few weeks. Another
           bone marrow biopsy, as well as blood tests, will be taken 3-4 months after the
           transplant to review the disease status. At this point, participants will come into the
           clinic about every 3 months, or as determined by their physician for about one year.

        -  While the study ends at 12 months after transplant, we would like to keep track of the
           participants medical condition for the rest of their life.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2006</start_date>
  <completion_date type="Actual">September 2011</completion_date>
  <primary_completion_date type="Actual">July 2010</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The Maximally Tolerated Dose (MTD) of Bortezomib (Velcade) That Can be Administered With Tacrolimus and Methotrexate After Mismatched Allogeneic Non-myeloablative Peripheral Blood Stem Cell (PBSC) Transplantation</measure>
    <time_frame>by day 45 post PBSC infusion</time_frame>
    <description>The MTD of bortezomib was evaluated at 3 dose levels:
Dose level 1: 1.0 mg/m^2 Dose level 2: 1.3 mg/m^2 Dose level 3: 1.5 mg/m^2 Cohorts of 3-5 pts were enrolled at each dose level. At any dose level, if no DLT in the first 3, 4, or 5 pts, then dose escalation would occur.
If 3 evaluable pts in cohort, and 1 of 3 experiences DLT then 2 additional pts treated at the same dose level. If &gt;=1 of 2 additional pts experience DLT then previous dose level will be MTD. If no DLT in additional 2 pts then dose escalation will occur. If 4 evaluable pts in cohort, and 1 of the 4 experiences DLT then 1 additional pt treated at same dose level. If this additional pt experiences DLT then the previous dose will be declared to be the MTD. If additional pt does not experience DLT, then dose escalation will take place. If 5 evaluable pts in cohort, and 1 experiences DLT, then dose escalation will take place. If &gt;=2 of first 3, 4, or 5 pts experience DLT then the previous dose will be declared MTD.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Successful Initial Engraftment by Day 45 Post Peripheral Blood Stem Cell (PBSC) Infusion and Administration of Bortezomib (Velcade), Tacrolimus and Methotrexate</measure>
    <time_frame>by day 45 post PBSC infusion</time_frame>
    <description>Percentage of participants who did not experience failure to engraft or relapse or death before assessment.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of Grade II-IV Acute Graft Versus Host Disease (GVHD) by Day 100.</measure>
    <time_frame>by day 100 after peripheral blood stem cell (PBSC) infusion</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Sustained Engraftment Following Transplant.</measure>
    <time_frame>by day 100 post transplant</time_frame>
    <description>As measured by median total donor chimerism at day 100.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Chronic Graft Versus Host Disease (Chronic GVHD).</measure>
    <time_frame>by 1 year after PBSC infusion</time_frame>
    <description>Number of participants with chronic GVHD at 1 year post transplant.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival and Progression-free Survival.</measure>
    <time_frame>by 1 year after PBSC infusion</time_frame>
    <description>Progression is defined as disease relapse or disease progression since transplant.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">45</enrollment>
  <condition>Hematologic Malignancies</condition>
  <arm_group>
    <arm_group_label>Bortezomib/Tacrolimus/Methotrexate post HSCT</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bortezomib (Velcade)</intervention_name>
    <description>Infusion for a total of 3 doses</description>
    <arm_group_label>Bortezomib/Tacrolimus/Methotrexate post HSCT</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tacrolimus</intervention_name>
    <description>Taken until Doctor determines it is not necessary any more</description>
    <arm_group_label>Bortezomib/Tacrolimus/Methotrexate post HSCT</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Methotrexate</intervention_name>
    <description>Infusion for a total of 4 doses</description>
    <arm_group_label>Bortezomib/Tacrolimus/Methotrexate post HSCT</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>blood stem cell transplantation</intervention_name>
    <description>Allogeneic Non-myeloablative peripheral blood stem cell transplantation</description>
    <arm_group_label>Bortezomib/Tacrolimus/Methotrexate post HSCT</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with hematologic malignancies including myelodysplastic syndrome (MDS), who
             are at a high risk of complications after myeloablative transplantation

          -  Patients have a donor (both related and unrelated) who are mismatched according to
             protocol criteria

          -  18 years of age or older

          -  Performance status 0-2

          -  Life expectancy of &gt; 100 days

          -  Female subject is either post-menopausal or sterilized or willing to use an acceptable
             form of birth control

          -  Male subject agrees to use an acceptable form of birth control

        Exclusion Criteria:

          -  Evidence of HIV infection

          -  Total bilirubin &gt; 2.0mg/dl that is due to hepatocellular dysfunction

          -  Aspartate aminotransferase (AST) &gt; 90

          -  Known active hepatitis B or C

          -  Serum creatinine &gt; 2.0

          -  Greater than or equal to Grade 2 peripheral neuropathy within 21 days of enrollment

          -  Prior allogeneic stem cell transplant

          -  Patients with myeloproliferative disease (e.g. myelofibrosis, essential
             thrombocythemia, polycythemia vera, chronic myeloid leukemia)

          -  Myocardial infarction within 6 months prior to enrollment or has NYHA Class III or IV
             hear failure, uncontrolled angina, severe uncontrolled ventricular arrhythmias, or
             electrocardiographic evidence of acute ischemia or active conduction system
             abnormalities

          -  Hypersensitivity to Velcade, boron or mannitol

          -  Pregnant or breast feeding

          -  Patient has received other investigational drugs 14 days before enrollment

          -  Serious medical or psychiatric illness

          -  Another active solid tumor malignancy at the time of study entry
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>John Koreth, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Dana-Farber Cance Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Brigham and Women's Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dana-Farber Cancer Institute</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 24, 2006</study_first_submitted>
  <study_first_submitted_qc>August 24, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 29, 2006</study_first_posted>
  <results_first_submitted>August 8, 2012</results_first_submitted>
  <results_first_submitted_qc>June 19, 2013</results_first_submitted_qc>
  <results_first_posted type="Estimate">July 25, 2013</results_first_posted>
  <last_update_submitted>June 19, 2013</last_update_submitted>
  <last_update_submitted_qc>June 19, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 25, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Dana-Farber Cancer Institute</investigator_affiliation>
    <investigator_full_name>John Koreth, MD</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Velcade</keyword>
  <keyword>Bortezomib</keyword>
  <keyword>Allogeneic Stem Cell Transplant</keyword>
  <keyword>GVHD</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Graft vs Host Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Methotrexate</mesh_term>
    <mesh_term>Tacrolimus</mesh_term>
    <mesh_term>Bortezomib</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Phase I (45 Days)</title>
          <description>Bortezomib plus tacrolimus and methotrexate after mismatched allogeneic non-myeloablative hematopoietic stem cell transplantation (HSCT).</description>
        </group>
        <group group_id="P2">
          <title>Phase II (45 Days)</title>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Phase I (45 Days)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="13"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="13">Once MTD established, additional 10 patients were accrued at MTD to better estimate toxicity.</participants>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Phase II (45 Days)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="32"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="32">This includes 10 patients treated at candidate MTD in Phase I.</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Phase I</title>
        </group>
        <group group_id="B2">
          <title>Phase II</title>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="13"/>
            <count group_id="B2" value="32"/>
            <count group_id="B3" value="45"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="25"/>
                    <measurement group_id="B3" value="38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="18"/>
                    <measurement group_id="B3" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="32"/>
                    <measurement group_id="B3" value="45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>The Maximally Tolerated Dose (MTD) of Bortezomib (Velcade) That Can be Administered With Tacrolimus and Methotrexate After Mismatched Allogeneic Non-myeloablative Peripheral Blood Stem Cell (PBSC) Transplantation</title>
        <description>The MTD of bortezomib was evaluated at 3 dose levels:
Dose level 1: 1.0 mg/m^2 Dose level 2: 1.3 mg/m^2 Dose level 3: 1.5 mg/m^2 Cohorts of 3-5 pts were enrolled at each dose level. At any dose level, if no DLT in the first 3, 4, or 5 pts, then dose escalation would occur.
If 3 evaluable pts in cohort, and 1 of 3 experiences DLT then 2 additional pts treated at the same dose level. If &gt;=1 of 2 additional pts experience DLT then previous dose level will be MTD. If no DLT in additional 2 pts then dose escalation will occur. If 4 evaluable pts in cohort, and 1 of the 4 experiences DLT then 1 additional pt treated at same dose level. If this additional pt experiences DLT then the previous dose will be declared to be the MTD. If additional pt does not experience DLT, then dose escalation will take place. If 5 evaluable pts in cohort, and 1 experiences DLT, then dose escalation will take place. If &gt;=2 of first 3, 4, or 5 pts experience DLT then the previous dose will be declared MTD.</description>
        <time_frame>by day 45 post PBSC infusion</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Phase I</title>
          </group>
        </group_list>
        <measure>
          <title>The Maximally Tolerated Dose (MTD) of Bortezomib (Velcade) That Can be Administered With Tacrolimus and Methotrexate After Mismatched Allogeneic Non-myeloablative Peripheral Blood Stem Cell (PBSC) Transplantation</title>
          <description>The MTD of bortezomib was evaluated at 3 dose levels:
Dose level 1: 1.0 mg/m^2 Dose level 2: 1.3 mg/m^2 Dose level 3: 1.5 mg/m^2 Cohorts of 3-5 pts were enrolled at each dose level. At any dose level, if no DLT in the first 3, 4, or 5 pts, then dose escalation would occur.
If 3 evaluable pts in cohort, and 1 of 3 experiences DLT then 2 additional pts treated at the same dose level. If &gt;=1 of 2 additional pts experience DLT then previous dose level will be MTD. If no DLT in additional 2 pts then dose escalation will occur. If 4 evaluable pts in cohort, and 1 of the 4 experiences DLT then 1 additional pt treated at same dose level. If this additional pt experiences DLT then the previous dose will be declared to be the MTD. If additional pt does not experience DLT, then dose escalation will take place. If 5 evaluable pts in cohort, and 1 experiences DLT, then dose escalation will take place. If &gt;=2 of first 3, 4, or 5 pts experience DLT then the previous dose will be declared MTD.</description>
          <units>mg/m^2</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Successful Initial Engraftment by Day 45 Post Peripheral Blood Stem Cell (PBSC) Infusion and Administration of Bortezomib (Velcade), Tacrolimus and Methotrexate</title>
        <description>Percentage of participants who did not experience failure to engraft or relapse or death before assessment.</description>
        <time_frame>by day 45 post PBSC infusion</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Combined Phase I Plus Phase II</title>
            <description>This reports on the total phase I plus phase II patients who were evaluable for chimerism endpoint (37 of the 45 patients).</description>
          </group>
        </group_list>
        <measure>
          <title>Successful Initial Engraftment by Day 45 Post Peripheral Blood Stem Cell (PBSC) Infusion and Administration of Bortezomib (Velcade), Tacrolimus and Methotrexate</title>
          <description>Percentage of participants who did not experience failure to engraft or relapse or death before assessment.</description>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="37"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Incidence of Grade II-IV Acute Graft Versus Host Disease (GVHD) by Day 100.</title>
        <time_frame>by day 100 after peripheral blood stem cell (PBSC) infusion</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Phase I and Phase II</title>
            <description>This reports on all treated patients across both phase I and phase II (n=45)</description>
          </group>
        </group_list>
        <measure>
          <title>Incidence of Grade II-IV Acute Graft Versus Host Disease (GVHD) by Day 100.</title>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="45"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22" lower_limit="11" upper_limit="35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Sustained Engraftment Following Transplant.</title>
        <description>As measured by median total donor chimerism at day 100.</description>
        <time_frame>by day 100 post transplant</time_frame>
        <population>Several subjects experienced failure to graft, relapse or death prior to assessment and were removed from analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Phase I and Phase II</title>
            <description>Engraftment is determined for all treated patients across both phase I and phase II (n=45) who are evaluable for this endpoint (n=35)</description>
          </group>
        </group_list>
        <measure>
          <title>Sustained Engraftment Following Transplant.</title>
          <description>As measured by median total donor chimerism at day 100.</description>
          <population>Several subjects experienced failure to graft, relapse or death prior to assessment and were removed from analysis.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="35"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Incidence of Chronic Graft Versus Host Disease (Chronic GVHD).</title>
        <description>Number of participants with chronic GVHD at 1 year post transplant.</description>
        <time_frame>by 1 year after PBSC infusion</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Phase I and Phase II</title>
            <description>This reports on all treated patients across both phase I and phase II (n=45)</description>
          </group>
        </group_list>
        <measure>
          <title>Incidence of Chronic Graft Versus Host Disease (Chronic GVHD).</title>
          <description>Number of participants with chronic GVHD at 1 year post transplant.</description>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="45"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29" lower_limit="16" upper_limit="43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Overall Survival and Progression-free Survival.</title>
        <description>Progression is defined as disease relapse or disease progression since transplant.</description>
        <time_frame>by 1 year after PBSC infusion</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Progression-free Survival (PFS)</title>
            <description>This reports on all treated patients across both phase I and phase II (n=45)</description>
          </group>
          <group group_id="O2">
            <title>Overall Survival (OS)</title>
            <description>This reports on all treated patients across both phase I and phase II (n=45)</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Survival and Progression-free Survival.</title>
          <description>Progression is defined as disease relapse or disease progression since transplant.</description>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="45"/>
                <count group_id="O2" value="45"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="60" lower_limit="44" upper_limit="73"/>
                    <measurement group_id="O2" value="76" lower_limit="60" upper_limit="86"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>By day 45 post PBSC infusion.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Phase I-II</title>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="45"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Febrile neutropenia</sub_title>
                <description>CTCAE grade 3</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="45"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Parainfluenzae sinusitis</sub_title>
                <description>CTCAE grade 3</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Clostridium difficile diarrhea</sub_title>
                <description>CTCAE grade 3</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Coagulase-negative staphylococcal bacteremia</sub_title>
                <description>CTCAE grade 3</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="45"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Cerebrovascular accident with parathesias</sub_title>
                <description>CTCAE grade 3</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="45"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperglycemia</sub_title>
                <description>CTCAE grade 3</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="45"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Deep vein thrombosis/pulmonary embolus</sub_title>
                <description>CTCAE grade 3</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="45"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="45"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>John Koreth, MBBS, D.Phil</name_or_title>
      <organization>Dana-Farber Cancer Institute</organization>
      <phone>(617) 632-2949</phone>
      <email>jkoreth@partners.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

